A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis

Takeo Toshima, Ken Shirabe, Toru Ikegami, Tomoharu Yoshizumi, Atsushi Kuno, Akira Togayachi, Masanori Gotoh, Hisashi Narimatsu, Masaaki Korenaga, Masashi Mizokami, Akihiro Nishie, Shinichi Aishima, Yoshihiko Maehara

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Background: Recently, a novel marker, hyperglycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), was developed for liver fibrosis using the glycan “sugar chain”-based immunoassay; however, the feasibility of WFA+-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.

Methods: Serum WFA+-M2BP values were evaluated in 200 patients with chronic liver disease who underwent histological examination of liver fibrosis. The diagnostic accuracy of WFA+-M2BP values was compared with various fibrosis markers, such as ultrasound based-virtual touch tissue quantification (VTTQ), magnetic resonance imaging based-liver-to-major psoas muscle intensity ratio (LMR), and serum markers, including hyaluronic acid, type 4 collagen, and aspartate transaminase to platelet ratio index (APRI).

Results: Serum WFA+-M2BP levels in patients with fibrosis grades F0, F1, F2, F3, and F4 had cutoff indices 1.62, 1.82, 3.02, 3.32, and 3.67, respectively, and there were significant differences between fibrosis stages F1 and F2, and between F2 and F3 (P < 0.01). The area under the receiver operating characteristic curves for the diagnosis of fibrosis (F ≥ 3) using serum WFA+-M2BP values (0.812) was almost comparable to that using VTTQ examination (0.814), but was superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) (P < 0.01 each).

Conclusions: Serum WFA+-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method for the assessment of liver fibrosis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.

Original languageEnglish
Pages (from-to)76-84
Number of pages9
JournalJournal of Gastroenterology
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Liver Cirrhosis
Carrier Proteins
Biomarkers
Fibrosis
Collagen Type IV
Touch
Hyaluronic Acid
Serum
Immunoassay
Hepatitis
Polysaccharides
Psoas Muscles
Aspartate Aminotransferases
ROC Curve
Liver Diseases
Chronic Disease
Blood Platelets
Magnetic Resonance Imaging
wisteria lectin
Liver

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis. / Toshima, Takeo; Shirabe, Ken; Ikegami, Toru; Yoshizumi, Tomoharu; Kuno, Atsushi; Togayachi, Akira; Gotoh, Masanori; Narimatsu, Hisashi; Korenaga, Masaaki; Mizokami, Masashi; Nishie, Akihiro; Aishima, Shinichi; Maehara, Yoshihiko.

In: Journal of Gastroenterology, Vol. 50, No. 1, 01.01.2014, p. 76-84.

Research output: Contribution to journalArticle

Toshima, Takeo ; Shirabe, Ken ; Ikegami, Toru ; Yoshizumi, Tomoharu ; Kuno, Atsushi ; Togayachi, Akira ; Gotoh, Masanori ; Narimatsu, Hisashi ; Korenaga, Masaaki ; Mizokami, Masashi ; Nishie, Akihiro ; Aishima, Shinichi ; Maehara, Yoshihiko. / A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis. In: Journal of Gastroenterology. 2014 ; Vol. 50, No. 1. pp. 76-84.
@article{ec59c7faddd54ca0832281d3d6afa42a,
title = "A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis",
abstract = "Background: Recently, a novel marker, hyperglycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), was developed for liver fibrosis using the glycan “sugar chain”-based immunoassay; however, the feasibility of WFA+-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.Methods: Serum WFA+-M2BP values were evaluated in 200 patients with chronic liver disease who underwent histological examination of liver fibrosis. The diagnostic accuracy of WFA+-M2BP values was compared with various fibrosis markers, such as ultrasound based-virtual touch tissue quantification (VTTQ), magnetic resonance imaging based-liver-to-major psoas muscle intensity ratio (LMR), and serum markers, including hyaluronic acid, type 4 collagen, and aspartate transaminase to platelet ratio index (APRI).Results: Serum WFA+-M2BP levels in patients with fibrosis grades F0, F1, F2, F3, and F4 had cutoff indices 1.62, 1.82, 3.02, 3.32, and 3.67, respectively, and there were significant differences between fibrosis stages F1 and F2, and between F2 and F3 (P < 0.01). The area under the receiver operating characteristic curves for the diagnosis of fibrosis (F ≥ 3) using serum WFA+-M2BP values (0.812) was almost comparable to that using VTTQ examination (0.814), but was superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) (P < 0.01 each).Conclusions: Serum WFA+-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method for the assessment of liver fibrosis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.",
author = "Takeo Toshima and Ken Shirabe and Toru Ikegami and Tomoharu Yoshizumi and Atsushi Kuno and Akira Togayachi and Masanori Gotoh and Hisashi Narimatsu and Masaaki Korenaga and Masashi Mizokami and Akihiro Nishie and Shinichi Aishima and Yoshihiko Maehara",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00535-014-0946-y",
language = "English",
volume = "50",
pages = "76--84",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis

AU - Toshima, Takeo

AU - Shirabe, Ken

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

AU - Kuno, Atsushi

AU - Togayachi, Akira

AU - Gotoh, Masanori

AU - Narimatsu, Hisashi

AU - Korenaga, Masaaki

AU - Mizokami, Masashi

AU - Nishie, Akihiro

AU - Aishima, Shinichi

AU - Maehara, Yoshihiko

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Recently, a novel marker, hyperglycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), was developed for liver fibrosis using the glycan “sugar chain”-based immunoassay; however, the feasibility of WFA+-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.Methods: Serum WFA+-M2BP values were evaluated in 200 patients with chronic liver disease who underwent histological examination of liver fibrosis. The diagnostic accuracy of WFA+-M2BP values was compared with various fibrosis markers, such as ultrasound based-virtual touch tissue quantification (VTTQ), magnetic resonance imaging based-liver-to-major psoas muscle intensity ratio (LMR), and serum markers, including hyaluronic acid, type 4 collagen, and aspartate transaminase to platelet ratio index (APRI).Results: Serum WFA+-M2BP levels in patients with fibrosis grades F0, F1, F2, F3, and F4 had cutoff indices 1.62, 1.82, 3.02, 3.32, and 3.67, respectively, and there were significant differences between fibrosis stages F1 and F2, and between F2 and F3 (P < 0.01). The area under the receiver operating characteristic curves for the diagnosis of fibrosis (F ≥ 3) using serum WFA+-M2BP values (0.812) was almost comparable to that using VTTQ examination (0.814), but was superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) (P < 0.01 each).Conclusions: Serum WFA+-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method for the assessment of liver fibrosis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.

AB - Background: Recently, a novel marker, hyperglycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), was developed for liver fibrosis using the glycan “sugar chain”-based immunoassay; however, the feasibility of WFA+-M2BP for assessing liver fibrosis has not been proven with clinical samples of hepatitis.Methods: Serum WFA+-M2BP values were evaluated in 200 patients with chronic liver disease who underwent histological examination of liver fibrosis. The diagnostic accuracy of WFA+-M2BP values was compared with various fibrosis markers, such as ultrasound based-virtual touch tissue quantification (VTTQ), magnetic resonance imaging based-liver-to-major psoas muscle intensity ratio (LMR), and serum markers, including hyaluronic acid, type 4 collagen, and aspartate transaminase to platelet ratio index (APRI).Results: Serum WFA+-M2BP levels in patients with fibrosis grades F0, F1, F2, F3, and F4 had cutoff indices 1.62, 1.82, 3.02, 3.32, and 3.67, respectively, and there were significant differences between fibrosis stages F1 and F2, and between F2 and F3 (P < 0.01). The area under the receiver operating characteristic curves for the diagnosis of fibrosis (F ≥ 3) using serum WFA+-M2BP values (0.812) was almost comparable to that using VTTQ examination (0.814), but was superior to the other surrogate markers, including LMR index (0.766), APRI (0.694), hyaluronic acid (0.683), and type 4 collagen (0.625) (P < 0.01 each).Conclusions: Serum WFA+-M2BP values based on a glycan-based immunoassay is an accurate, reliable, and reproducible method for the assessment of liver fibrosis. This approach could be clinically feasible for evaluation of beneficial therapy through the quantification of liver fibrosis in hepatitis patients if this measurement application is commercially realized.

UR - http://www.scopus.com/inward/record.url?scp=84894879627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894879627&partnerID=8YFLogxK

U2 - 10.1007/s00535-014-0946-y

DO - 10.1007/s00535-014-0946-y

M3 - Article

C2 - 24603981

AN - SCOPUS:84894879627

VL - 50

SP - 76

EP - 84

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 1

ER -